Hemostemix Inc. (CVE:HEM – Get Free Report) was up 27.3% during mid-day trading on Thursday . The stock traded as high as C$0.07 and last traded at C$0.07. Approximately 278,000 shares were traded during mid-day trading, an increase of 336% from the average daily volume of 63,759 shares. The stock had previously closed at C$0.06.
Hemostemix Trading Up 15.4 %
The company’s 50-day simple moving average is C$0.05 and its 200-day simple moving average is C$0.05. The stock has a market capitalization of C$6.53 million, a price-to-earnings ratio of -1.88 and a beta of 0.18.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Recommended Stories
- Five stocks we like better than Hemostemix
- 5 Top Rated Dividend Stocks to Consider
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Election Stocks: How Elections Affect the Stock Market
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
